This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cystinuria / Dibasic aminoaciduria type II / SLC3A1/SLC7A9 deficiency시스틴뇨증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E72.0 (cystinuria) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCystinuria, dibasic aminoaciduria type II, SLC3A1 deficiency (rBAT deficiency), SLC7A9 deficiency (b⁰ʺAT deficiency), renal cystine stone disease
C. Adult onsetLikelihood of first onset in adulthood high — cystinuria also presents in childhood, but the first urinary stone event often occurs between adolescence and the 30s, so first diagnosis in adulthood is common; urinary cystine supersaturation is present from birth, but the age at which stones form varies widely, and abnormal urinary amino acids are sometimes found incidentally in asymptomatic carriers.
1. History1810 Wollaston first isolated cystine from a bladder stone → 1908 Garrod classified it as an inborn error of metabolism → 1950s renal tubular reabsorption defect identified → 1994 SLC3A1 (rBAT) cloned → 1999 SLC7A9 (b⁰ʺAT) mutations identified → 2024 AUA guideline revised.
2. CausesPathogenic variants in SLC3A1 (2p21, encoding rBAT) or SLC7A9 (19q13.11, encoding b⁰ʺAT) → impaired reabsorption of cystine, ornithine, lysine, and arginine in the proximal tubule and small intestine → excess urinary cystine → cystine crystallization at low pH → urinary stones.
3. GeneticsSLC3A1 variants: autosomal recessive (type AA). SLC7A9 variants: autosomal recessive (type BB); heterozygous carriers may also be symptomatic (incomplete recessive). A mixed type (type AB) also exists. More than 200 variants reported worldwide. Full phenotype in homozygotes/compound heterozygotes.
4. General epidemiologyAbout 1 in 7,000 births worldwide (1:7,000). 6–8% of pediatric urinary stones and 1–2% of all urinary stones. Stones occur more frequently in males than females. High prevalence in Libyan Jews due to the founder mutation SLC3A1 M467T. Cystinuria is rare among Korean patients with urinary stones, but case reports exist.
5. PathophysiologyThe SLC7A9/SLC3A1 heterodimer transporter reabsorbs cystine, ornithine, lysine, and arginine (COLA) at the apical membrane of the proximal tubule. Variants cause loss of transporter function → all four amino acids increase in the urine. Cystine (a disulfide amino acid) has extremely low solubility at low pH (about 300 mg/L at pH 5.0), leading to crystallization and stone formation. Lysine, ornithine, and arginine are sufficiently soluble at this pH and do not form stones.
6. SymptomsRecurrent urinary stones: flank pain (renal colic), hematuria, urinary frequency, dysuria. Recurrent urinary tract infections (stone-related). Decline in kidney function (due to recurrent stones, surgery, and infection). Pediatric: first presentation with abdominal pain, hematuria, or urinary tract infection. Some patients progress to bilateral nephrolithiasis or nephrocalcinosis.
7. SignsAbdominal/lower back pain; radiating pain during renal colic (groin, scrotum, labia). Hematuria (gross or microscopic). Urine pH: generally low (5.0–6.0). Bilateral stones and hydronephrosis on renal ultrasound/CT. Hexagonal cystine crystals on urine microscopy (pathognomonic finding).
8. ScreeningQualitative urine cystine test: nitroprusside reaction (cyanide-nitroprusside test) — if positive (red/purple), urinary cystine ≥75 mg/L is suspected. Urine microscopy: hexagonal cystine crystals. Quantitative urine amino acids (diagnostic if 24-hour urine cystine >400 mg/day). Cystine stones confirmed on urinary stone composition analysis.
9. Diagnosis24-hour urine amino acid quantification (LC-MS/MS): cystine >400 mg/day (affected), >100 mg/day (carrier); simultaneous elevation of COLA (cystine, ornithine, lysine, arginine). Urine cystine/creatinine ratio (pediatric: >0.3 mg/mg). SLC3A1 and SLC7A9 gene analysis (NGS panel). Stone composition analysis (infrared spectroscopy): cystine stones confirmed. Hexagonal crystals on urine microscopy.
10. TreatmentFoundational therapy: adequate fluid intake (target urine volume ≥3.5 L/day, including overnight), low-salt, low-protein diet (reducing methionine, the cystine precursor). Urinary alkalinization: maintain urine pH 7.0–7.5 with potassium citrate (increases cystine solubility). Drug therapy: tiopronin (α-mercaptopropionylglycine) or D-penicillamine forms mixed cystine-drug disulfides → increased cystine solubility. Surgery: extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL), ureteroscopic lithotripsy (URS).
11. PrognosisCystinuria is a chronic, recurrent urinary stone disease. Active treatment (adequate fluids, alkalinization, drugs) can reduce the frequency of stone recurrence. As recurrent stones, urinary tract infections, and surgeries accumulate, kidney function declines. In long-term follow-up cohorts, the rate of ESRD is about 1–4%. With poor treatment adherence, stones recur and quality of life is markedly reduced.
12. PreventionPrimary: genetic counseling (families with confirmed SLC3A1/SLC7A9 variants, recurrence risk 25%). Secondary: education on adequate fluid intake (3–4 L per day, including before bed and after waking), low-salt, low-protein diet, self-measurement of urine pH, regular monitoring of urinary cystine. Tertiary: maintaining adherence to drugs (tiopronin/D-penicillamine), regular follow-up of kidney function and renal imaging.
13. ReferencesDello Strologo L et al. J Am Soc Nephrol. 2002 … and 9 other papers

1. History

The history of cystinuria is closely linked to the history of urinary stone research. In 1810, the Englishman William Hyde Wollaston isolated a new substance from a bladder stone and named it 'cystic oxide'; it was later renamed cystine. The name cystine derives from the bladder (cystis). In 1908, the British physician Archibald Garrod included cystinuria as one of four inborn errors of metabolism in his book Inborn Errors of Metabolism, contributing to establishing the concept of hereditary biochemical disease.

In the 1950s, a defect in the reabsorption of cystine and the dibasic amino acids (lysine, arginine, ornithine) in the small intestine and renal tubules was identified as the pathophysiology of this disease. In 1964, Rosenberg et al. proposed a phenotypic classification system dividing patients with cystinuria into three types (types I, II, and III), based on the residual capacity for cystine reabsorption and the presence or absence of aminoaciduria in heterozygous carriers. In 1994, Calonge et al. were the first to identify variants in the SLC3A1 (rBAT) gene on chromosome 2 as the cause of type I cystinuria.

In 1999, the second causative gene, SLC7A9 (b⁰ʺAT), was cloned on chromosome 19, establishing the genetic basis of non-type I cystinuria. Current classification of cystinuria has been simplified according to the causative gene into SLC3A1 variants (type A), SLC7A9 variants (type B), and a mixed type (type AB). In terms of treatment, D-penicillamine was introduced in the 1960s–1970s, and in 1988 tiopronin, with fewer adverse effects, received FDA approval. In 2024, the latest cystinuria guideline from the American Urological Association (AUA) was published, updating the evidence-based management framework for fluid intake, alkalinization, and drug therapy.


2. Causes

Cystinuria is an autosomal recessive genetic disease in which pathogenic variants in the SLC3A1 or SLC7A9 gene impair the reabsorption of cystine and the dibasic amino acids (cystine, ornithine, lysine, arginine: COLA) in the epithelial cells of the proximal tubule and small intestine.

The SLC7A9 gene is located on chromosome 19 (19q13.11) and encodes the b⁰ʺAT (b0,+ amino acid transporter 1) protein. b⁰ʺAT is the functional transport subunit that carries neutral and dibasic amino acids such as cystine, ornithine, lysine, and arginine into the cell. The SLC3A1 gene is located on chromosome 2 (2p21) and encodes the rBAT (related to b0,+ amino acid transporter) protein. rBAT forms a heterodimer linked to b⁰ʺAT by a disulfide bond and targets the transporter complex to the apical membrane of the proximal tubule. Because the heterodimer of the two proteins constitutes the functional cystine/dibasic amino acid transporter complex, a loss-of-function variant in either gene abolishes COLA reabsorption.

When the urinary cystine concentration rises, cystine precipitates as hexagonal crystals in the low-pH environment of the urine, forming cystine stones. Lysine, ornithine, and arginine are sufficiently soluble in urine and do not form stones. Cystine stones are hard and difficult to pass spontaneously, and because of their low radiopacity they must be confirmed by CT rather than plain X-ray.


3. Genetics

The mode of inheritance of cystinuria differs somewhat depending on the causative gene.

SLC3A1 variants (type A): Fully autosomal recessive. The full phenotype appears in homozygous or compound heterozygous patients. Heterozygous carriers have no or minimal urinary amino acid abnormalities and rarely form stones. The SLC3A1 gene is located on the short arm of chromosome 2 (2p21) and is about 105 kb in size.

SLC7A9 variants (type B): Incompletely autosomal recessive. Even in heterozygous carriers, urinary cystine and dibasic amino acids are partially elevated, and stones can rarely form (incomplete recessive; clinical symptoms can occur even when only a single variant is identified on genetic testing). Full phenotype in homozygotes or compound heterozygotes. The SLC7A9 gene is on chromosome 19 (19q13.11) and is about 13 kb in size.

Variant spectrum: More than 200 pathogenic variants have been reported worldwide. In SLC3A1, R270X, M467T, T216M, and others are relatively common, and M467T is a founder mutation in Libyan Jews. In SLC7A9, G105R, V170M, A182T, and others are known. Genotype-phenotype correlation is incomplete, but loss-of-function variants in SLC3A1 are generally associated with a more severe stone burden. NGS-based panels analyzing both genes simultaneously are used for molecular diagnosis.


4. General epidemiology

Cystinuria is a relatively rare genetic disease occurring worldwide in about 1 in 7,000 births. However, it accounts for 6–8% of pediatric urinary stones and 1–2% of all urinary stones, making it the most common hereditary stone disease. Stone-related clinical symptoms tend to occur more frequently in males than in females, which is presumed to be due to anatomic (urinary tract length) and hormonal factors.

Regionally, a very high incidence of 1 in 2,500 births is reported in Middle Eastern Jews, particularly Libyan Jews, because of the SLC3A1 M467T founder mutation. In the general European population, the proportions of type A (SLC3A1) and type B (SLC7A9) are similar, at about 45–50%:50–55%. Prevalence data for East Asia, including Korea, are limited, but cystinuria should be considered in the differential diagnosis of patients presenting with pediatric hematuria or urinary stones.

Age at first stone ranges from childhood to the 40s, with a mean age at first stone of about 10–25 years. After diagnosis, the mean annual number of stone events without treatment is about 1–2, and dozens of stones and repeated surgeries over a lifetime seriously affect quality of life.


5. Pathophysiology

The pathophysiology of cystinuria is explained by excess urinary cystine due to loss of reabsorption of cystine (and the dibasic amino acids) in the proximal tubule.

Transporter mechanism: Normally, in the S1 segment of the proximal tubule (brush border, apical membrane), the SLC7A9-SLC3A1 heterodimer transporter actively reabsorbs cystine and the COLA amino acids into the cell. This transporter operates by exchange transport (antiporter), bringing one neutral amino acid (mainly a sodium-independent neutral amino acid) into the cell while simultaneously exporting one dibasic amino acid or cystine out of the cell. Cystine is an oxidized, disulfide-bonded amino acid that the transporter recognizes as a substrate and reabsorbs into the cell.

With a loss-of-function variant in SLC7A9 or SLC3A1, this transporter complex is not properly targeted to the apical membrane or loses its catalytic function, so reabsorption of cystine (and COLA) does not occur. As a result, daily urinary cystine excretion increases to 400–2,000 mg/day, dozens of times the normal level (30–50 mg/day).

Stone formation mechanism: Cystine has a low solubility of about 250–300 mg/L at urine pH 5.0. At urine pH 7.5, solubility roughly doubles to about 500 mg/L. When the urinary cystine concentration exceeds its solubility, hexagonal crystals form and grow into stones in the renal collecting system. The stones have low radiopacity (semi-opaque) and are poorly visible on plain abdominal X-ray (KUB), but appear on CT as stones of homogeneous density.

Small intestine involvement: Damage to the same transporter in small intestinal epithelial cells also reduces intestinal absorption of cystine, but cysteine, a product of protein hydrolysis, is absorbed, so the systemic cystine supply is maintained. Therefore, cystinemia does not occur in cystinuria.


6. Symptoms

The main clinical manifestation of cystinuria is recurrent urinary stone formation; there are no other systemic symptoms.

Urinary stone symptoms: Renal colic is the most characteristic and serious symptom of cystinuria. Sudden severe flank pain radiates to the groin, testes, or labia majora and is accompanied by nausea and vomiting. Hematuria (gross or microscopic) is observed in most cases. Urinary frequency, dysuria, and urinary tract infections occur in association with stones. In children, abdominal pain, hematuria, and recurrent urinary tract infections appear as the first symptoms, and the radiating pain typical of renal colic may not be clear.

Symptoms of complications: As recurrent stones and surgeries (extracorporeal shock wave lithotripsy, percutaneous nephrolithotomy) accumulate, renal parenchymal damage occurs, which can lead to proteinuria, hypertension, and decline in kidney function. When bilateral nephrolithiasis or hydronephrosis progresses, uremic symptoms (fatigue, edema, anemia) appear. Recurrent urinary tract infections lead to pyelonephritis and renal scarring.

Asymptomatic form: Heterozygous carriers (particularly SLC7A9 type B) have mildly elevated urinary cystine and dibasic amino acids, but in some cases no stones form.


7. Signs

The physical signs of cystinuria consist mainly of findings associated with urinary stones.

Abdominal and urologic signs: During renal colic, tenderness and percussion tenderness at the costovertebral angle (CVA) on the affected side are characteristic. Abdominal guarding may be present, requiring differentiation from an acute abdomen. Fever and leukocytosis appear when a urinary tract infection is present.

Urinalysis signs: Hexagonal cystine crystals on urine microscopy are a specific finding. Hematuria (numerous red blood cells). Urine pH: usually acidic (5.0–6.0). Urine protein: positive when kidney damage has progressed.

Imaging findings: Non-contrast abdominopelvic CT: stones appear with homogeneous density, with higher sensitivity than plain X-ray or ultrasound. Cystine stones are semi-opaque, so they may appear faint or not be visible on KUB X-ray. Renal ultrasound: useful for identifying the acoustic shadow of stones and hydronephrosis. With chronic kidney damage, reduced kidney size, cortical atrophy, and renal scarring are observed.

Nitroprusside reaction: A qualitative screening test in which adding nitroprusside (sodium cyanide-nitroprusside) to fresh urine produces a purple (magenta) reaction at cystine concentrations of 75 mg/L or higher.


8. Screening

Screening for cystinuria is performed stepwise based on clinical suspicion (urinary stones in children and adolescents, family history).

Step 1 — qualitative screening: The nitroprusside (cyanide-nitroprusside) reaction is applied to fresh urine. A purple-to-red reaction suggests urinary cystine ≥75 mg/L. Good sensitivity, low specificity (false positives possible with penicillin, acetoacetic acid, etc.). If this test is positive, proceed to confirmatory testing.

Step 2 — urine microscopy: When freshly collected urine is examined under the microscope, hexagonal or plate-like cystine crystals are seen. These crystals are almost specific to cystinuria, and when found, quantitative testing should follow immediately.

Step 3 — 24-hour urine cystine quantification: 24-hour urinary cystine excretion (mg/day) is measured by LC-MS/MS. Affected patients: ≥400 mg/day. Heterozygous carriers (type B): 100–400 mg/day. Normal: <100 mg/day. In children, the urine cystine/creatinine ratio (mg/mg) is used (suspected if >0.3 mg/mg).

Family history-based screening: Quantitative urine amino acid screening is recommended for siblings and children of patients with cystinuria. Because stones occasionally occur even in heterozygous carriers of SLC7A9 type B, clinical monitoring of heterozygous family members is needed.


9. Diagnosis

Cystinuria is confirmed by urinary cystine quantification and genetic analysis.

24-hour urine cystine quantification (confirmatory test): Cystine, ornithine, lysine, and arginine are quantified by LC-MS/MS or ion-exchange chromatography. All four are elevated in affected patients, and cystine ≥400 mg/24 hours is the diagnostic criterion. Quantitative testing is also used to monitor treatment response (target: maintain <250 mg/L or <300 mg/24 hours).

SLC3A1 and SLC7A9 gene analysis: Pathogenic variants are detected with an NGS-based panel covering both genes simultaneously or with whole-exome analysis. Confirming the genotype is important for genetic counseling, carrier identification, and prognostic prediction. In some patients in whom no variant is identified, RNA analysis or functional testing is additionally performed.

Stone composition analysis: Stones passed spontaneously or retrieved surgically are analyzed by infrared spectroscopy or X-ray powder diffraction. Identification of a pure cystine stone (100% cystine) or a mixed cystine stone strongly supports cystinuria.

Kidney function assessment: In patients with a history of recurrent stones and surgery, serum creatinine, eGFR, 24-hour urine protein, and renal ultrasound are assessed periodically to detect decline in kidney function early.


10. Treatment

The key goal of cystinuria treatment is to prevent stone formation by keeping the urinary cystine concentration below the crystallization threshold (generally 250–300 mg/L or <300 mg/24 hours).

Increased fluid intake: Urine volume is increased to at least 3.5 L per day to dilute cystine. To prevent nocturnal urine concentration, a regular fluid intake schedule is needed, including an additional 500 mL before bed and drinking water on waking. The goal is to maintain urine specific gravity ≤1.010. Adequate fluid intake is the foundation at every stage of treatment.

Dietary modification: Dietary sodium restriction (<2 g/day) reduces urinary sodium-cystine co-excretion. Protein restriction (especially animal protein) reduces the supply of methionine (the cystine precursor). Citrate-rich foods (lemon water) help alkalinize the urine.

Urinary alkalinization: Urine pH is maintained at 7.0–7.5 with potassium citrate (60–80 mEq/day in 3 divided doses). Above pH 7.0, cystine solubility increases sharply (about 500–1,000 mg/L), suppressing stone formation. Monitoring 2–3 times a day using a home urine pH meter (test strips) is recommended.

Drug therapy: If urinary cystine <300 mg/24 hours is not achieved with fluids and alkalinization alone, tiopronin (α-MPG, 800–1,200 mg/day in 3 divided doses) or D-penicillamine (1–2 g/day) is added. Both drugs undergo an exchange reaction with the disulfide bond of cystine (thiol-disulfide exchange) to form mixed disulfides with higher solubility. Tiopronin is preferred because it has fewer adverse effects (nephrotic syndrome, hematologic abnormalities) than D-penicillamine.

Surgical treatment: Extracorporeal shock wave lithotripsy (ESWL): because cystine stones are hard, they respond poorly, and it is less effective than for ordinary stones. Ureteroscopic lithotripsy (URS): effective for ureteral stones. Percutaneous nephrolithotomy (PCNL): standard treatment for large kidney stones. Minimally invasive approaches are preferred to minimize kidney damage.


11. Prognosis

Cystinuria is a chronic, recurrent disease requiring ongoing management, and prognosis varies greatly depending on treatment adherence and the frequency of stone recurrence.

Stone recurrence: Without treatment, about 1–2 stone events occur per year. Adherence to adequate fluid intake, alkalinization, and drug therapy can reduce the frequency of stone recurrence by 50–70%. However, with poor adherence, stones recur frequently. Fluid intake (especially at night) and pH maintenance are cited as the most difficult adherence components.

Renal prognosis: As recurrent stones, urinary tract infections, and surgeries accumulate, kidney function declines. Long-term follow-up studies report that 1–4% of patients with cystinuria reach ESRD. Stones involving both kidneys, early onset (childhood), and treatment nonadherence are risk factors for worsening kidney function.

Quality of life: Recurrent renal colic, repeated surgeries, and drug adverse effects (especially nephrotic syndrome with D-penicillamine and gastrointestinal symptoms with tiopronin) seriously affect quality of life. Psychological stress and disruption of work and school are also substantial. Patient education and participation in support groups help long-term adherence.


12. Prevention

Prevention in cystinuria aims at long-term stone prevention and preservation of kidney function.

Primary prevention: In families of patients with cystinuria, the recurrence risk (25%) is explained through genetic counseling, and urine amino acid screening of siblings and children is recommended. The possibility of mild symptoms in heterozygous SLC7A9 carriers on genetic analysis is also explained. Prenatal diagnosis is technically possible, but thorough genetic counseling considering the variable phenotype and treatability of cystinuria should come first.

Secondary prevention: Immediately upon diagnosis, education on fluid intake (3–4 L per day, including overnight) and dietary modification (low-salt, low-protein) begins. A home urine pH measuring device (test strips) is provided, and pH monitoring 2–3 times a day is taught. Potassium citrate is given to maintain urine pH at 7.0–7.5. In patients at high risk of stone recurrence (urinary cystine >1,000 mg/24 hours, recurrent stones), tiopronin is added early.

Tertiary prevention: Regular (every 6–12 months) quantitative urine cystine measurement confirms whether treatment goals are met. Renal ultrasound or non-contrast CT once a year monitors stone recurrence and changes in kidney function. Serum creatinine, eGFR, and proteinuria are measured regularly to detect decline in kidney function early, and addition of a RAAS blocker is considered.


13. References

  1. Dello Strologo L, Pras E, Pontesilli C, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol. 2002;13(10):2547–2553. DOI: 10.1097/01.asn.0000029586.17680.e5 PMID: 12239248.

  2. Palacin M, Goodyer P, Nunes V, Gasparini P. Cystinuria. In: The Metabolic and Molecular Bases of Inherited Disease. 2001:4909–4932. (Scriver CR et al., eds.).

  3. Calonge MJ, Gasparini P, Chillaron J, et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet. 1994;6(4):420–425. DOI: 10.1038/ng0494-420 PMID: 8054986.

  4. Botzenhart EM, Vester U, Schmidt C, et al. Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int. 2002;62(4):1136–1142. DOI: 10.1111/j.1523-1755.2002.t01-1-kid574.x PMID: 12234284.

  5. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–324. DOI: 10.1016/j.juro.2014.05.006 PMID: 24857648.

  6. Servais A, Thomas K, Dello Strologo L, et al. Cystinuria: clinical practice recommendation. Kidney Int. 2021;99(1):48–58. DOI: 10.1016/j.kint.2020.06.035 PMID: 32877705.

  7. Sayer JA. Progress in understanding the genetics of calcium-containing nephrolithiasis. J Am Soc Nephrol. 2017;28(3):748–759. DOI: 10.1681/ASN.2016050576 PMID: 27864432.

  8. Andreassen KH, Pedersen KV, Osther SS, et al. How should patients with cystine stone disease be evaluated and treated in the twenty-first century? Urolithiasis. 2016;44(1):65–76. DOI: 10.1007/s00240-015-0841-1 PMID: 26688429.

  9. Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006;69(6):1041–1047. DOI: 10.1038/sj.ki.5000183 PMID: 16528247.

  10. Biyani CS, Bhatt JR, Bhatt R, et al. Cystinuria: current management and future prospects. Int Urol Nephrol. 2017;49(2):221–228. DOI: 10.1007/s11255-016-1450-8 PMID: 27837459.